SCHEMBL21140593

SCHEMBL21140593

CCN(CCOC)C(=O)N1CCN(C)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.69
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 4/20 0.51
MAPT P10636 2/20 0.51
LMNA P02545 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.42
NAMPT P43490 2/20 0.40
MLYCD O95822 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
CYP1A2 P05177 1/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18390292 0.92 HTR1A (0.59) HTR1AKDM4EALDH1A1MAPTLMNA
SCHEMBL21140592 0.84 HTR1A (0.47) HTR1AKDM4EALDH1A1MAPTLMNA
Diethylcarbamazine SCHEMBL1819685 0.82 HTR1A (1.00) HTR1AKDM4EALDH1A1MAPTLMNA
Diethylcarbamazine SCHEMBL67289 0.82 HTR1A (1.00) HTR1AKDM4EALDH1A1MAPTLMNA
Diethylcarbamazine SCHEMBL10412471 0.81 HTR1A (0.96) HTR1AKDM4EALDH1A1MAPTLMNA
SCHEMBL18713103 0.80 HTR1A (0.49) HTR1AKDM4EALDH1A1MAPTLMNA
Diethylcarbamazine SCHEMBL2719699 0.79 HTR1A (0.92) HTR1AKDM4EALDH1A1MAPTLMNA
SCHEMBL11096507 0.78 HTR1A (0.89) HTR1AKDM4EALDH1A1MAPTLMNA
SCHEMBL11506548 0.77 HTR1A (0.74) HTR1AKDM4EALDH1A1MAPTLMNA
SCHEMBL18705042 0.75 HRH3 (0.41) HTR1AKDM4EALDH1A1MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766869-B2 Triazoles for the treatment of demyelinating dieases VERTEX PHARMACEUTCALS INCORPORATED (US) 2020-09-08 US disclosed
US-20190185436-A1 TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMA (US) 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766869-B2 Triazoles for the treatment of demyelinating dieases PMP22, MYT1, IDE HTR1A 4191/4885KDM4E 1313/4885ALDH1A1 568/4885
US-20190185436-A1 TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES PMP22, MYT1, IKZF3 HTR1A 3306/4885KDM4E 1833/4885ALDH1A1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.